KAIROS PHARMA LTD (KAPA) Stock Income Statement
NYSEARCA:KAPA - NYSE Arca - US48301N1046 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 3.32M | 2.34M | 1.71M | 571.00K | 1.94M | |||
| Research and Development | 742.00K | 414.00K | 82.00K | 87.00K | 183.00K | |||
| Selling, General, and Administrative Expenses | 2.46M | 1.77M | 1.63M | 484.00K | 1.76M | |||
| Operating Income | -3.32M | -2.34M | -1.71M | -571.00K | -1.94M | |||
| Interest Income/Expense | -824.00K | -859.00K | -98.00K | -459.00K | -164.00K | |||
| Other Income/Expense | N/A | N/A | 0.00 | -20.00K | -38.00K | |||
| Non Recurring Items | N/A | 599.00K | N/A | N/A | N/A | |||
| Income Before Taxes | -3.54M | -2.60M | -1.81M | -1.05M | -2.15M | |||
| Net Income | -3.54M | -2.60M | -1.81M | -1.05M | -2.15M | |||
| EBITDA | -3.16M | -2.18M | -1.55M | -411.00K | -1.84M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.27 | -0.23 | -0.14 | -0.08 | -0.17 | |||
| Statistics | ||||||||
All data in USD